Menu
← Oncology Approval Tracker
FDA DECISION ·
Poherdy
pertuzumab-dpzb · Shanghai Henlius Biologics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
An interchangeable biosimilar to Perjeta for approved HER2-positive breast cancer uses with trastuzumab and chemotherapy: previously untreated metastatic disease, eligible neoadjuvant disease, and high-risk early disease in the adjuvant setting.
LAMPGEN ANALYSIS
Why it matters
This was the first FDA-approved pertuzumab biosimilar, with interchangeability determined at approval.
What research teams should watch
Update product-level ordering, lot traceability, and cardiac assessment workflows before formulary use.
PRIMARY RECORDS